Preventing Cardiovascular Events in Our Patients With PCSK9 Inhibition

Target Audience
This educational activity is directed toward general internists and internal medicine subspecialists who treat patients with lipid disorders. Nurse practitioners, physician assistants, nurses, and other health care professionals involved in lipid management are invited to participate.

Program Overview
This online, on-demand virtual symposium brings together renowned experts in cardiovascular disease. In this educational program, these experts use a case-based format to discuss the latest evidence and guidelines regarding cardiovascular risk reduction, particularly strategies for secondary prevention in patients at high risk who are likely to benefit from non-statin therapies such as PCSK9 inhibitors.

This educational activity is an archive of the live virtual symposium held on April 30, 2021.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Identify patients most likely to benefit from the addition of non-statin therapies to their treatment regimen
Assess recent efficacy and safety data and guideline recommendations for the use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors for cardiovascular risk reduction in patients who have not achieved lipid treatment goals
Select appropriate therapies for patients with cardiovascular risk who are not at lipid treatment goals, based on patient-centered considerations
Analyze current evidence regarding the relationship between cost-effectiveness data and access barriers for PCSK9 inhibitors